Cigna (CI) Stock Forecast & Price Target

Cigna Group is performing well in all aspects of its business, including its PBM and specialty pharmacy services which have been greatly expanded by its recent merger. The company's recent wins and contracts, low-bar expectations, and strong performance in a dynamic market indicate that the company's shares are likely to grind higher. Despite a decline in earnings for its PBM segment, the company's overall performance is strong and its outlook is positive.

Cigna Group is facing execution risks in predicting and managing medical cost trends and network contracting, as well as potential impact from regulatory changes on rebate economics. Furthermore, the company may also be affected by a potential economic downturn. However, Cigna's business mix and divestiture of HIX make it an attractive player in the payor space and potential long-term growth catalysts could reignite interest in the stock. The company's Specialty & Care segment is expected to continue growing at the high end of its range, driven by solid specialty volume growth, mix-shift towards biosimilars and specialty generics, and contributions from Shields. Despite concerns about execution risks, Cigna remains an innovative health plan with strong potential in a market with secular tailwinds.